India, Oct. 29 -- Iovance Biotherapeutics, Inc. (IOVA) is down 35.76 percent, losing $5.30 to $9.52 on the Thursday. The decline follows updated results from Cohorts 1 and 2 of the Phase 2 IOV-LUN-202 trial of lifileucel in previously treated non-squamous metastatic non-small cell lung cancer.
As of October 14, 17 of 69 patients responded, representing an overall response rate of 24.6 percent, compared with the previously reported 25.6 percent response rate among 39 patients.
Iovance is currently trading at $9.52, down from the previous close of $14.81 after opening at $10.62 on the Nasdaq. The stock has traded between $9.35 and $11.58 during the session. Trading volume stands at 41.68 million shares, compared with an average volume of 16...